www.pharmaceuticalonline.com Open in urlscan Pro
20.185.12.70  Public Scan

Form analysis
3 forms found in the DOM

GET /search

<form method="get" class="form-inline nav-search pr-0" action="/search">
  <input class="form-control-sm" name="keyword" type="search" maxlength="250" placeholder="Search" aria-label="Search">
  <button type="submit" class="btn-sm btn-dark">
    <i class="fas fa-search fa-sm"></i>
  </button>
</form>

POST /useremailonly/register?referringlink=sidebar-widget

<form class="vm-email-signup-form" action="/useremailonly/register?referringlink=sidebar-widget" method="post" novalidate="novalidate">
  <div class="ajax-loader">
    <span></span>
  </div>
  <img src="https://vertassets.blob.core.windows.net/sites/contentbribes/SubscribeToday.png" alt="Newsletter Signup" title="Newsletter Signup" class="vm-signup-img">
  <div class="validation-summary validation-summary-valid" style="display: none;" data-valmsg-summary="true">
    <ul>
      <li style="display:none"></li>
    </ul>
  </div>
  <p>Get the latest articles from Pharmaceutical Online delivered to your inbox.</p>
  <p class="vm-signup-highlighted-text"></p>
  <input type="hidden" data-val="true" data-val-required="The Source field is required." id="Source" name="Source" value="EmailReg-PHARM">
  <div class="form-group row">
    <div class="col-sm-12">
      <input type="text" class="form-control form-control-sm email-input-consent-check-trigger" placeholder="Email" maxlength="100" data-val="true" data-val-email="The Email field is not a valid e-mail address."
        data-val-required="You must enter a valid email address" id="Email" name="Email" value="">
      <span class="field-validation-valid" data-valmsg-for="Email" data-valmsg-replace="true"></span>
    </div>
  </div>
  <div class="form-row">
    <div class="col-sm-12">
      <div class="nl-consent-container" style="display: none;">
        <div class="form-check"><label class="form-check-label"><strong><input class="form-check-input" data-val="true" data-val-range="You must accept the Terms And Conditions." data-val-range-max="True" data-val-range-min="True"
                data-val-required="The NlConsent field is required." name="NlConsent" type="checkbox" value="true">I agree to the <a href="/static/legal">Terms</a>.</strong></label><span class="validation-message field-validation-valid"
            data-valmsg-for="NlConsent" data-valmsg-replace="true"></span></div>
      </div>
      <div class="client-consent-container" style="display: none;">
        <div class="form-check"><label class="form-check-label"><strong><input class="form-check-input" data-val="true" data-val-required="The ClientConsent field is required." name="ClientConsent" type="checkbox" value="true">I agree to the
              <a href="/static/privacy">Privacy Statement</a>.</strong></label><span class="validation-message field-validation-valid" data-valmsg-for="ClientConsent" data-valmsg-replace="true"></span></div>
      </div>
    </div>
  </div>
  <div class="row justify-content-end mt-3">
    <div class="col-12">
      <button type="submit" class="btn btn-block btn-sm vm-button">
        <i class="fa fa-arrow-right"></i>
        <span class="vm-button-text">SIGN ME UP</span>
      </button>
    </div>
  </div>
  <input name="__RequestVerificationToken" type="hidden" value="CfDJ8L4Tx_kqk_hOqQdWmadsynS0cestAAd1P_DSBsxEEFhvTPfFQBIJPrpZGXD88EXdSI9heje1sVOFx8WW2HrRdeztpxPJ9S96bXja_7rDy0osKc-6d8f7Yk0wEUcNxce5QT00d-cZa5VfWuuN7kslpJM">
</form>

POST /useremailonly/register?referringlink=popup

<form action="/useremailonly/register?referringlink=popup" method="post" novalidate="novalidate">
  <div class="modal-header no-gutters justify-content-between">
    <img src="https://vertassets.blob.core.windows.net/sites/contentbribes/Pharm-Online-Newsletter-Subscription-Pop-Up-Final.png" alt="Sign Up Now" title="Sign Up Now" class="img-fluid">
    <div class="vm-ajax-loader"><span></span></div>
    <button type="button" class="close" data-dismiss="modal" aria-hidden="true" onclick="hideConsent()">×</button>
  </div>
  <div class="modal-body">
    <input type="hidden" data-val="true" data-val-required="The Source field is required." id="Source" name="Source" value="PopUp-PHARM">
    <div class="form-group row no-gutters">
      <div class="col-sm pr-1">
        <input type="text" class="form-control email-input-consent-check-trigger" placeholder="Email" maxlength="100" data-val="true" data-val-email="The Email field is not a valid e-mail address."
          data-val-required="You must enter a valid email address" id="Email" name="Email" value="">
        <span class="field-validation-valid" data-valmsg-for="Email" data-valmsg-replace="true"></span>
      </div>
      <div class="col-sm-auto">
        <button type="submit" class="btn btn vm-button vm-alt-button">Subscribe</button>
      </div>
    </div>
    <div class="form-row">
      <div class="col-sm-10" pl-1="">
        <div class="nl-consent-container" style="display: none;">
          <div class="form-check"><label class="form-check-label"><strong><input class="form-check-input" data-val="true" data-val-range="You must accept the Terms And Conditions." data-val-range-max="True" data-val-range-min="True"
                  data-val-required="The NlConsent field is required." name="NlConsent" type="checkbox" value="true">I agree to the <a href="/static/legal">Terms</a>.</strong></label><span class="validation-message field-validation-valid"
              data-valmsg-for="NlConsent" data-valmsg-replace="true"></span></div>
        </div>
        <div class="client-consent-container" style="display: none;">
          <div class="form-check"><label class="form-check-label"><strong><input class="form-check-input" data-val="true" data-val-required="The ClientConsent field is required." name="ClientConsent" type="checkbox" value="true">I agree to the
                <a href="/static/privacy">Privacy Statement</a>.</strong></label><span class="validation-message field-validation-valid" data-valmsg-for="ClientConsent" data-valmsg-replace="true"></span></div>
        </div>
      </div>
    </div>
  </div>
  <input name="__RequestVerificationToken" type="hidden" value="CfDJ8L4Tx_kqk_hOqQdWmadsynS0cestAAd1P_DSBsxEEFhvTPfFQBIJPrpZGXD88EXdSI9heje1sVOFx8WW2HrRdeztpxPJ9S96bXja_7rDy0osKc-6d8f7Yk0wEUcNxce5QT00d-cZa5VfWuuN7kslpJM">
</form>

Text Content

Get more pharma manufacturing insight with our FREE newsletter sign me up

Sign in or Sign-up
Production
Critical Environments Solid Dose Manufacturing Liquid Dose Manufacturing
Packaging
Inspection Serialization Packaging
Outsourcing
Development Production Logistics
Quality
Regulatory Compliance Quality Assurance Quality Control
Research
Sourcing Centers
Bioprocessing Facility Design Inspection Packaging Process Equipment
Virtual Pharma Expo



GUEST COLUMN | AUGUST 18, 2021




PREFILLED SYRINGES: BEST PRACTICES FOR USING X-RAY ANALYSIS TO ASSESS CONTAINER
CLOSURE INTEGRITY

By Tim Sandle, Ph.D.

The presentation of pharmaceutical preparations in the form of prefilled
syringes continues to grow. The addition of drugs in prefilled insertable and
disposable cartridges is driven by manufacturing economics (including the
avoidance of overfill, common with dispensing into vials, which saves on product
yield); clinical preference, including better accuracy of dose delivery and
avoiding the cross-contamination that can occur with a separate syringe and
vial;1 and an expansion of medications that can be self-administered by the
patient in the home. The syringe plays a dual role in the prefilled syringe
product — as a container closure system and as a delivery device.

Prefilled syringes vary in terms of their method of manufacture, method of
filling syringes with a drug product, and the types of syringes available.2
Several variations are required due to product incompatibility in particular
drug combinations and material types.3 Products in prefilled syringes must be
chemically, physically, and biologically stable and, based on the route of
administration, the combination product must be sterile and apyrogenic. Product
manufacturing requirements are set out in the ISO 11040 standard, such as Part
8, which presents the “Requirements and test methods for finished prefilled
syringes.”4 One important aspect of assessing prefilled syringes relates to the
integrity of the filled syringe. The process of assessing integrity is generally
more complex than the process of assessing glass vials due to the presence of
more sealing areas. This article looks at the broad requirement, together with a
recent innovation for integrity testing based on X-rays.


ASSESSING STERILITY

The syringes provided for filling need to be sterile and, once filled, products
are subject to terminal sterilization, such as by ethylene oxide, radiation, or
moist heat (where the medicine is not rendered inefficacious by the
sterilization method)5 or presented as an aseptically filled product.


ASSESSMENT OF EMPTY AND FILLED SYRINGES

Testing empty syringes prior to filling generally relates to physical tests,
such as flange break resistance and needle penetration. The FDA and EMA have an
additional requirement that the syringe unit is sterile for sterile medicines.
The significance of sterility extends to the release of the syringe, which
requires a review of the sterility assurance of the batch. Included within the
sterility assurance framework is the sterility test, for which a specialized
adapter is required to enable the sequential testing of syringe contents and
needle surfaces using compendial membrane filtration sterility test
methodology.6 Sterility testing typically forms part of the end-product release
test and as an end-of-shelf-life test for those batches selected for stability
trials.


CONTAINER CLOSURE INTEGRITY

For both aseptically produced and terminally sterilized syringes, a critical
factor is the integrity of the syringe once it has been filled. This is assessed
through qualification testing, designed to assess the suitability of container
closure systems to maintain a sterile barrier against potential contaminants.
Replicating environmental factors is important, such as the temperature,
humidity, vibration, and pressure to which the combination product will be
subjected when stored and distributed. For reasons of transportation, do not
fill syringes to their full extent, to help minimize the potential for leakage
due to excessive sideways pressure applied the plunger during storage.

The most common method to assess integrity is the deterministic dye ingress
method (where a 1 g/L solution of methylene blue is used as the dye), although
there are alternative methods such as probabilistic microbial ingress (using the
bacterium Brevundimonas diminuta) as well as high-voltage leak detection and
vacuum/pressure decay testing and emergent methods such as X-ray imaging
analysis. As well as these methods to demonstrate integrity (and hence the
maintenance of sterility), vibrational effects can also lead to particulate
generation. Aside from the selection of the method, arguably the most important
factor is ensuring a statistically representative number of samples is used so
that any common cause defects can be assessed. The assessment of strength and
integrity must also apply to the outer packaging to assess the suitability of
the packaging seal.

Traditionally, professionals in our industry deploy a combination of a microbial
and physical test, although the direct microbial test has fallen out of favor in
recent years. The microbial test involves either a whole or partial immersion
method, with whole immersion preferred when it is necessary to test the
integrity of both the syringe hub and the plunger.  The physical dye intrusion
test is a simple and rapid test to evaluate batch to batch syringe performance,
enabling a greater number of syringes to be tested.


X-RAY IMAGING ANALYSIS

X-ray imaging analysis enables a large number of syringes to be processed, and
it potentially offers a faster and more accurate result than either the direct
microbial test or other physical tests. With speed, we can process hundreds of
syringes per hour using this technology, placing it ahead of most other methods.
The test is also nondestructive, which confers a further advantage.

The method originated with tableting, where a tablet microstructure is examined
to assess the proportion of the crystal particles.8 The technology involves
using a low energy X-ray source, with image recognition and processing
technology. The application of low energy means that the contents of the syringe
are not subjected to any significant rise in temperature. Radiation is produced
with a focal range, and it is the focus diameter that defines the spatial
resolution. This manifests as a series of X-ray pulses. The technology can be
used to identify syringes with bent needles and needles that puncture the caps.9

An X-ray based system is also capable of detecting functional defects such as
syringes with poor needle alignment. As technology advances, artificial
intelligence trained against image recognition will be able to aid in the
interpretation of the X-ray images (radiographs), including processing images of
fracture planes.

Professionals in the pharmaceutical and medical device industries could use this
technique not only for analysis of defects and failures but also to characterize
geometries and morphologies during the process and package development stage.
Moreover, as well as providing a method for the assessment of integrity,
professionals in our industry are applying energy dispersive X-ray spectroscopy
to troubleshoot foreign matters in pharmaceutical drug products.

Summary

Integrity testing of prefilled syringes is an important part of the sterility
assurance system, especially to demonstrate that integrity is maintained as part
of transportation. Various technologies are available, and X-ray
microtomographic imaging is an emerging method that has the advantage of being a
nondestructive technique for quantifying the risk of syringe integrity across
three dimensions. While the method remains in its infancy, it has the potential
to speed up the time and accuracy of prefilled syringe medicinal release.

References

 1. Van Grafhorst JP, Foudraine NA, Nooteboom F, Crombach WHJ, Oldenhof NJJ, Van
    Doorne H. Unexpected high risk of contamination with staphylococci species
    attributable to standard preparation of syringes for continuous intravenous
    drug administration in a simulation model in intensive care units. Crit Care
    Med 2002;30:833–6
 2. Sacha, G., J. Rogers, A., Miller, R. (2015) Pre-filled syringes: a review of
    the history, manufacturing and challenges, Pharmaceutical Development and
    Technology, 20:1, 1-11, DOI: 10.3109/10837450.2014.982825
 3. Eakins M. The design and construction of pre-filled syringes. Am Pharm
    Review. 2007;10(6):47–51
 4. ISO 11040-8:2016 Prefilled syringes — Part 8: Requirements and test methods
    for finished prefilled syringes, International Standards Organization,
    Geneva, Switzerland
 5. ISO 11607-1:2019 Packaging for terminally sterilized medical devices — Part
    1: Requirements for materials, sterile barrier systems and packaging
    systems, International Standards Organization, Geneva, Switzerland
 6. Challener, C. Test Methods and Quality Control for Prefilled Syringes,
    Pharmaceutical Technology Biologics and Sterile Drug Manufacturing eBook
    (May 2019).
 7. Parenteral Drug Association P. PDA Technical Report No. 27 (TR 27)
    Pharmaceutical Package Integrity. 1998
 8. Turner, T., Gajjar, P., Fragkopoulos, I. et al Measuring the Particle
    Packing of l-Glutamic Acid Crystals through X-ray Computed Tomography for
    Understanding Powder Flow and Consolidation Behavior, Crystal Growth &
    Design 2020 20 (7), 4252-4263
 9. Hindelang, F., Zurbach, R., Roggo, Y. Micro Computer Tomography for medical
    device and pharmaceutical packaging analysis, Journal of Pharmaceutical and
    Biomedical Analysis, 108: 38-48, 2015

About The Author:

Tim Sandle, Ph.D., is a pharmaceutical professional with wide experience in
microbiology and quality assurance. He is the author of more than 30 books
relating to pharmaceuticals, healthcare, and life sciences, as well as over 170
peer-reviewed papers and some 500 technical articles. Sandle has presented at
over 200 events and he currently works at Bio Products Laboratory Ltd. (BPL),
and he is a visiting professor at the University of Manchester and University
College London, as well as a consultant to the pharmaceutical industry. Visit
his microbiology website at https://www.pharmamicroresources.com.



Please enable JavaScript to view the comments powered by Disqus.


NEWSLETTER SIGNUP

 * 

Get the latest articles from Pharmaceutical Online delivered to your inbox.




I agree to the Terms.
I agree to the Privacy Statement.
SIGN ME UP


YOU MAY ALSO LIKE...

 * CONTAINER CLOSURE INTEGRITY TESTING METHOD DEVELOPMENT AND VALIDATION FOR
   PREFILLED SYRINGES
   
   In this article, we highlight our current thinking in an attempt to devise a
   systematic approach for CCI testing method selection, development, and
   validation.

 * CCI FOR COMBINATION PRODUCTS: ASSEMBLING THE PACKAGE INTEGRITY PROFILE FOR
   AUTOINJECTORS
   
   Due to their complexity, combination products, specifically autoinjection
   systems, present unique challenges in implementing a container closure
   integrity (CCI) testing strategy. This is further...

 * ASSESSING AND NAVIGATING TESTING FOR PARENTERAL PACKAGING AND DELIVERY
   SYSTEMS: PERFORMANCE TESTING
   
   There are many aspects to consider when developing a sound approach to
   performance testing to qualify packaging and delivery systems, and
   combination products.

 * CONTAINER CLOSURE INTEGRITY TESTING OF COMPLEX DRUG DELIVERY SYSTEMS
   
   New injection-delivery systems, such as auto-injectors, recombinant syringes,
   and retractable needles, have introduced new challenges, particularly for
   container closures.

 * WHICH TEST IS APPROPRIATE FOR CONTAINER CLOSURE INTEGRITY?
   
   Validation of container integrity must demonstrate no penetration of
   microbial contamination or gain or loss of any chemical or physical parameter
   deemed necessary to protect the product.

 * CHALLENGES AND PRACTICAL SOLUTIONS FOR SWITCHING TO PREFILLED SYRINGES FOR
   INJECTABLES

 * PTI MICRO LEAK TESTING FEATURED IN PDA JOURNAL

 * A PARADIGM SHIFT IN CONTAINER CLOSURE INTEGRITY OF PARENTERAL DRUGS

 * CONTAINER CLOSURE INTEGRITY TESTING: THE IMPORTANCE OF SENSITIVITY,
   AUTOMATION AND EFFICIENCY

 * PTI MICRO LEAK TESTING FEATURED IN PDA JOURNAL

 * SEE SOLUTIONS FOR CONTAINER CLOSURE INTEGRITY TESTING AT INTERPHEX

 * ASSESSING AND NAVIGATING TESTING FOR PARENTERAL PACKAGING AND DELIVERY
   SYSTEMS: CONTAINER CLOSURE INTEGRITY






×
Subscribe
I agree to the Terms.
I agree to the Privacy Statement.
This website uses cookies to ensure you get the best experience on our website.
Learn more
Got it!

PARTNER WITH US

 * Request More Information
 * Our Partners

SUBSCRIBE

 * Newsletter

LIFE SCIENCE CONNECT

 * Bioprocess Online
 * Biosimilar Development
 * Cell & Gene
 * Clinical Leader
 * Drug Discovery
 * Laboratory Network
 * Life Science Leader Magazine
 * Med Device Online
 * Outsourced Pharma

EDITORIAL

 * Archived Newsletters
 * Article Reprints
 * Editorial Submission Guidelines
 * The Expert Network

EVENTS

 * CMO Leadership Awards
 * CRO Leadership Awards

LEARN MORE

 * About Us
 * Contact Us
 * Work For Us


Copyright © 1996-2021 VertMarkets, Inc. All Rights Reserved. Terms of Use.
Privacy Statement. Subscriber Request Form. Don't sell my information